OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	165
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	36
Targeting RUNX1 Germline Variants: Agents Under Investigation	27
Monoclonal Gammopathy-Associated Neuropathy	26
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	25
Management of Chronic Myeloid Leukemia in Children and Young Adults	22
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	22
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	20
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications	19
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	19
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	19
Value in Myeloma Care: Myth or Reality	19
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	18
Allogeneic Transplant for CMML	18
Prognostic and Predictive Models in Myelofibrosis	16
How Do We Manage Chronic Lymphocytic Leukemia in India	15
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	14
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	14
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	14
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development	13
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	13
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	12
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	12
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	12
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	11

Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	10
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	10
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	9
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	8
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia	8
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	8
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	8
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	8
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	8
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	7
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera	7
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	7
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	7
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	7
Pediatric Germline Predisposition to Myeloid Neoplasms	7
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	6
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	6
Measurable Residual Disease Monitoring in Lymphoma	6
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	6
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	6
Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes	5
The Evolving Therapeutic Landscape of Richter Transformation	5
Managing Survivorship after Hematopoietic Cell Transplantation	5
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	5
Real-world Management of CML: Outcomes and Treatment Patterns	5
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies	4
The Role of Inflammation in CMML Pathobiology and Progression	4
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	4
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma	4
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	4
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	4
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	4
Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review	4
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	4
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	4